Skip to main content
. 2018 Apr 17;18(7):1774–1782. doi: 10.1111/ajt.14738

Figure 1.

Figure 1

MFI between baseline and month 24 in the subsets of patients in BENEFIT and BENEFIT‐EXT with preexisting DSAs. Dashed lines denote MHC class II preexisting DSAs. CsA, cyclosporine; DSA, donor‐specific antibody; LI, less intense; MFI, mean fluorescence intensity; MHC, major histocompatibility complex; MI, more intense